摘要:
Disclosed is use of a porous membrane and a composite membrane thereof in a redox flow batteries, and in particular the use thereof in a vanadium redox flow battery. The membrane can effectively realize the separation of ions with different valence states, and an ion transfer without any ion exchange group. The pore size and structure of the porous membrane can be controlled by filling an inorganic substance or grafting an ion exchange group in the pore, in order to improve the barrier properties of the porous membrane for vanadium ions and to increase proton conductivity.
摘要:
The present invention is concerned with certain novel spiro substituted heterocylic ring derivatives. These compounds may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of pharmaceutical formulations for the treatment of lipoxygenase-mediated disorders.
摘要:
The present invention discloses an alumina carrier for a silver catalyst, a process for preparing the alumina carrier, a silver catalyst made from the alumina carrier, and a use of the silver catalyst in the production of ethylene oxide by the oxidization of ethylene. The alumina carrier comprises alumina and promoters, as well as titanium silicate molecular sieve(s); and therefore, has an improved catalytic activity.
摘要:
Disclosed is use of a porous membrane and a composite membrane thereof in a redox flow batteries, and in particular the use thereof in a vanadium redox flow battery. The membrane can effectively realize the separation of ions with different valence states, and an ion transfer without any ion exchange group. The pore size and structure of the porous membrane can be controlled by filling an inorganic substance or grafting an ion exchange group in the pore, in order to improve the barrier properties of the porous membrane for vanadium ions and to increase proton conductivity.
摘要:
The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondrial disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.